Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bio Rad Laboratories Inc BIO

Alternate Symbol(s):  BIO.B

Technology Scientific & Technical Instruments
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and... see more

Recent & Breaking News (NYSE:BIO)

Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

PR Newswire June 6, 2021

Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

PR Newswire June 6, 2021

Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

PR Newswire June 6, 2021

FDA Approves First Treatment for Patients with Plasminogen Deficiency, a Rare Genetic Disorder

PR Newswire June 4, 2021

Amgen To Present At The Goldman Sachs 42nd Annual Global Healthcare Conference

PR Newswire June 4, 2021

2021 Cade Prize for Innovation Accepting Entries

PR Newswire June 4, 2021

Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)

Canada NewsWire June 4, 2021

FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014

PR Newswire June 4, 2021

Singapore/ US based TurtleTree ready to commercialize Human Lactoferrin as first major product

PR Newswire June 4, 2021

Hackensack University Medical Center and Hackensack Meridian School of Medicine Welcome Howard M. Ross, M.D. as Chair of Surgery/Surgeon-in-Chief

PR Newswire June 4, 2021

Strata Oncology Presents Data at ASCO 2021 Showing Comprehensive Genomic and Transcriptomic Profiling Predicts Pan-Tumor Benefit of Pembrolizumab

PR Newswire June 4, 2021

Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting

PR Newswire June 4, 2021

Ichnos Sciences Presents Preclinical Data Confirming Potential For ISB 1342 In Relapsed/Refractory Multiple Myeloma At 2021 ASCO Annual Meeting

PR Newswire June 4, 2021

Natera Announces New Prospera(TM) Data at the ATC 2021 Virtual Connect Conference

PR Newswire June 4, 2021

DCISionRT by PreludeDx Identifies Women with DCIS with Unacceptably High Rates of Local Recurrence after Breast Conserving Surgery and Radiation Therapy

PR Newswire June 4, 2021

AIkido Pharma Announces Positive Phase 1 Data Presented at ASCO on 225Ac-J591

PR Newswire June 4, 2021

Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)

PR Newswire June 4, 2021

Brooks Automation to Participate in the 13th Annual Virtual CEO Investor Summit 2021

PR Newswire June 4, 2021

Equifund Successfully Raises Over $1 Million for Biopact CT Via Reg-CF

PR Newswire June 4, 2021

Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches

PR Newswire June 4, 2021